Active Filter(s):
Details:
The funds will be mainly used to enhance its artificial intelligence (AI)-driven novel drug R&D platform, accelerate the preclinical development of several new medicine pipelines and expand international business cooperation.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Undisclosed
Partner/Sponsor/Collaborator: Sky9 Capital
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing February 18, 2021